CLINICAL IMPACT OF 18F FDG PET-CT ON MANAGEMENT OF GERM CELL TUMORS
Purpose: The purpose of this study was to review the impact of 18F- fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) scans on the management of patients with germ cell tumours (GCT) at our centre.
Methods: A descriptive, cross-sectional, retrospective review of a total of 29 FDG PET-CT scans acquired in 20 patients with GCT between December 2009 and May 2013.
Results: Sixteen males and four females with the average age of 34.4 years (+18SD) were identi ed who underwent FDG PET-CT scans for treatment response/outcome evaluation on an average period of 3 months after completion of therapy. Hypermetabolic residual disease (PET-CT positive) was identi ed in 8 (40%). 6 (30%) had non-FDG-avid residual morphologic disease (PET negative and CT positive) and 6 (30%) were disease free (PET-CT negative). FDG PET-CT led to change in the management plan of 12 (60%) of cases as compared to the CT alone ndings. Follow-up was available for a median of 2.9 years (±1.5 SD). The overall 5-year disease-free survival was found to be PET-CT positive patients = 62%, PET-negative and CT-positive patients = 80% and PET-CT-negative patients = 100%.
Conclusion: FDG PET-CT scanning has a potential role in the evaluation of response to treatment and can predict the survival outcome.
Key words: 18F- uorodeoxyglucose positron emission tomography computed tomography, disease-free survival, germ cell tumour, standardised uptake value
Chief P. Recent advances in molecular and cell biology of testicular germ-cell tumours. Int Rev Cell Mol Biol 2014;312: 79 100.
Treglia G, Sadeghi R, Annunziata S, et al. Diagnostic performance of uorine-18- uorodeoxyglucose positron emission tomography in the post chemotherapy management of patients with seminoma: Systematic review and meta- analysis. Biomed Res Int 2014;2014:852681.
Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med 1998;39:815-22.
Oldenburg J, Fossa SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24: 25-32.
Tsatalpas P, Beuthien-Baumann B, Kropp J, et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumours. Urol Int 2002;68:157-63.
Gerl A, Clemm C, Schmeller N, et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 1994;70:960-5.
De Santis M, Maj-Hes A, Bachner M. Positron Emission Tomography (PET) in Germ Cell Tumours (GCT). Imaging in Oncological Urology. London: Springer; 2009. p. 305-13.
Bhatti AB, Ahmed I, Ghauri RK, et al. Clinical profile, treatment and survival outcome of testicular tumors:APakistani perspective.Asian Pac J Cancer Prev 2014;15:277-80.
Bachner M, LoriotY, Gross-Goupil M, etal.2-18 fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for post chemotherapy seminoma residual lesions: A retrospective validation of the SEMPET trial. Ann Oncol 2012;23: 59-64.
Becherer A, De Santis M, Karanikas G, et al. FDG PET is superior to CT in the prediction of viable tumour in post- chemotherapy seminoma residuals. Eur J Radiol 2005;54: 284-8.
De Santis M, Becherer A, Bokemeyer C, et al. 2-18 uoro- deoxy-D-glucose POSITRON emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: An update of the prospective multicentric SEMPET trial J Clin Oncol 2004;22:1034-9.
Sharma P, Jain TK, Parida GK, et al. Diagnostic accuracy of integrated (18)F-FDG PET/CT for restaging patients with malignant germ cell tumours. Br J Radiol 2014; 87:20140263.
Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: Testicular cancer. J Natl Compr Canc Netw 2009;7:672-93.
Buchler T, Dusek P, Brisuda A, et al. A positron emission tomography and clinical predictors of survival in primary extragonadal germ cell tumors. Klin Onkil 2012;25:178-83.
Buchler T, Simonova K, Fencl P, et al. Clinical outcomes of patients with nonseminimatous germ cell tumours and negative post chemotherapy positrom emission tomography. Cancer Invest 2012;25:487-92.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.